LIBERTY ASTHMA QUEST
2018
Dupilumab in Moderate-to-Severe Uncontrolled Asthma
In 1,902 patients with uncontrolled moderate-to-severe asthma, dupilumab 200 or 300 mg every 2 weeks reduced severe exacerbations and improved FEV1 compared with placebo.
Result
Primary endpoint: Co-primary: annualised severe exacerbation rate and change in FEV1 at week 12
Severe exacerbation rate reduced 47.7% (200 mg) / 46% (300 mg) vs placebo, both P<0.001; FEV1 placebo-adjusted +0.14 L at wk 12, P<0.001. Greater effect at higher baseline blood eosinophils.
- Subtopic
- Anti-IL-4Rα biologic
- Design
- Multicentre phase-3 RCT
- Relevance
- Important: one of several pillars.
- Cited in
- ERS/ATS 2020 Severe Asthma
- Source
- Castro M, et al. N Engl J Med. 2018;378(26):2486-2496.doi 10.1056/NEJMoa1804092
Discussion & critique
Approved dupilumab for moderate-to-severe type-2 asthma.